Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Breyna is a prescription inhalation aerosol containing budesonide, an inhaled corticosteroid, and formoterol fumarate, a long-acting beta2-adrenergic agonist. It is approved for asthma in patients age 6 and older and for maintenance treatment of airflow obstruction and reduction of exacerbations in chronic obstructive pulmonary disease. It is not used for rapid relief of acute bronchospasm.
read more about breyna ...Budesonide binds glucocorticoid receptors and reduces inflammatory activity in the airways. Formoterol stimulates beta2-adrenergic receptors on airway smooth muscle, increasing cyclic AMP and relaxing bronchial muscle. The combination pairs anti-inflammatory corticosteroid activity with long-acting bronchodilation for ongoing asthma or chronic obstructive pulmonary disease treatment.
Breyna is approved for asthma in patients age 6 and older. It is also approved for maintenance treatment of airflow obstruction and reduction of exacerbations in chronic obstructive pulmonary disease, including chronic bronchitis or emphysema. It is not indicated for relief of sudden bronchospasm.
Patients age 12 and older with asthma use two inhalations of 80 mcg with 4.5 mcg or 160 mcg with 4.5 mcg twice daily. Children age 6 to under 12 use two inhalations of 80 mcg with 4.5 mcg twice daily. Chronic obstructive pulmonary disease uses two inhalations of 160 mcg with 4.5 mcg twice daily.
Breyna can cause oral candidiasis, lower respiratory infections, adrenal effects, reduced bone mineral density, slowed growth in children, cataracts, glaucoma, paradoxical bronchospasm, and cardiovascular effects. Patients rinse the mouth with water without swallowing after inhalation. A short-acting bronchodilator is used for sudden breathing symptoms.
Breyna contains budesonide, an inhaled corticosteroid, and formoterol fumarate, a long-acting beta2-adrenergic agonist.
Breyna is used twice daily, with two inhalations taken at each scheduled dose.
Yes. Current labeling includes asthma treatment in patients age 6 and older.
No. Breyna is not indicated for rapid relief of acute bronchospasm.
BREYNA Patient Information. https://www.breyna.com/-/media/breynacom/pdf/breyna_patient_information_or_what_is_breyna.pdf. Date Accessed September 16, 2026.
Budesonide and Formoterol Oral Inhalation. MedlinePlus. https://medlineplus.gov/druginfo/meds/a623022.html. Date Accessed September 16, 2026.
DailyMed - BREYNA (budesonide and formoterol fumarate) aerosol, metered. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc529fc4-bddb-4673-8202-dc401f86166f. Date Accessed September 16, 2026.
FDA Approval Letter - BREYNA (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211699Orig1s000ltr.pdf. Date Accessed September 16, 2026.
FDALabel - BREYNA (budesonide and formoterol fumarate). https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/641634. Date Accessed September 16, 2026.